News | August 20, 2014

New Dementia Research Reveals Overwhelming Demand for ‘Value of Knowing’

August 20, 2014 — Three out of four people would want to know what kind of neurological disorder they had, even if there was no cure, according to new global research from GE Healthcare. An even higher percentage of respondents, 81 percent, would want to identify an incurable neurological disorder if it affected somebody close to them, with more women (84 percent) wanting to know than men (76 percent). The “Value of Knowing” global survey of 10,000 adults across 10 countries explored perspectives on incurable neurological disorders including Alzheimer’s (AD) and Parkinson’s (PD) disease.

Prepared to Pay for Diagnosis

While the overwhelming consensus (94 percent) is that government or health insurance providers should cover diagnosis, approximately half (51 percent) of respondents indicated they would even be prepared to pay for a diagnosis themselves. This sentiment was particularly prevalent in India and China, where 71 percent and 83 percent respectively, said they would be prepared to pay. This was echoed by almost one half of those questioned in Russia and around one-third of respondents in the United Kingdom, United States and Japan.

“What these statistics tell us is just how strongly people feel about tackling neurological disorders like dementia,” said Marc Wortmann, executive director of Alzheimer’s Disease International. “Worldwide, nearly 44 million people have dementia, and this number is expected to nearly double in 20 years as the world’s population ages. Although there is no cure yet, a timely diagnosis is useful for people with dementia to get access to current treatment, services and support, both medical and non-medical.”

When people surveyed were asked why they would want to know, the most common answer (71 percent) was to start treatment that could help manage the symptoms of the disease. Other reasons included the opportunity to change their lifestyle to potentially slow the impact of the illness (66 percent), and the ability to make informed decisions (62 percent). Those who would not want to know cited undue worry and the futility of knowing about their disorder without being able to control it.

Ben Newton, director of PET (positron emission tomography) neurology for GE Healthcare, said, “It’s understandable that dementia is a frightening topic for people. That said, although there are currently no cures for many neurological disorders, there are symptom-modifying therapies and approaches available if detected early enough. It’s interesting to note that the majority of respondents with more experience of a neurological disorder via a loved one for example, said that they would want to know, in spite of there being no cure.”

Recognizing the Symptoms

The research also probed respondents’ recognition of the possible signs and symptoms of dementia. While a majority recognized memory loss (70 percent) and disorientation (61 percent) as signs of dementia, less than half of those surveyed were able to identify other very common symptoms, including language problems, personality, mood and behavior changes, and loss of initiative.

Newton added, “Understanding and knowing all the symptoms of a neurological disorder are critical to helping loved ones who may be showing early signs. Acting early on any concerns may mean patients have access to earlier diagnosis and intervention, which could help to manage and delay the impact of a disorder.”

US Specific Country Findings

The U.S. recorded 80 percent willingness to know. In addition, U.S. women wanted to know their own diagnosis more than men (81 percent vs. 79 percent). Eighty-five percent of U.S. respondents said they would want access to early diagnosis, and 96 percent feel early diagnosis should be covered by health insurance.

The research was conducted by Millward Brown during June 2014 across 10 countries — Australia, Brazil, China, India, Indonesia, Japan, Russia, South Korea, U.K. and U.S. — with 1,000 nationally representative adult respondents in each market.

For more information: www.gehealthcare.com

Related Content

ASNC and SNMMI Release Joint Document on Diagnosis, Treatment of Cardiac Sarcoidosis
News | Cardiac Imaging | August 18, 2017
August 18, 2017 — The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document wi
Houston Methodist Hospital Enters Multi-Year Technology and Research Agreement With Siemens Healthineers
News | Imaging | August 17, 2017
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge...
Study Demonstrates First Human Application of Novel PET Tracer for Prostate Cancer

Transaxial 11Csarcosine hybrid PET/CT showed a (triangulated) adenocarcinoma in the transition zone of the anterior right prostate gland on PET (A), CT (B), and a separately obtained T2?weighted MR sequence (C) with resulting PET/MRI registration (D). Image courtesy of M. Piert et al., University of Michigan, Ann Arbor, Mich.

News | Radiopharmaceuticals and Tracers | August 16, 2017
In the featured translational article in the August issue of The Journal of Nuclear Medicine, researchers at the...
PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
Novel PET Tracer Detects Small Blood Clots

PET images (MIP 0-60 min) of three Cynomolgus monkeys. Strong signals are detected at the sites where inserted catheters had roughened surfaces. Almost no other background signal is visible. Only accumulation in the gallbladder becomes visible at the bottom of the image. Credit: Piramal Imaging GmbH, Berlin Germany.

News | PET Imaging | July 07, 2017
July 7, 2017 — Blood clots in veins a
Sponsored Content | Videos | Clinical Decision Support | June 29, 2017
Rami Doukky, M.D., system chair, Division of Cardiology, professor of medicine, Cook County Health and Hospitals Syst
Dual-Agent PET/MR With Time of Flight Detects More Cancer

Tc-99m MDP bone scan (left) is negative for osseous lesions. NaF/FDG PET/MRI (right and second slide) confirms absence of bone metastases, but shows liver metastases. Image courtesy of Stanford University.

News | PET-MRI | June 20, 2017
Simultaneous injections of the radiopharmaceuticals fluorine-18 fluorodeoxyglucose (18F-FDG) and 18F-sodium fluoride (...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Overlay Init